Abstract
Optimal treatment for HER2/neu-positive, node-positive early breast cancer should include the monoclonal antibody trastuzumab. This relatively new agent has shown very limited pulmonary toxicity. Our report describes a case of life-threatening interstitial pneumonitis associated with Guillain-Barré syndrome that occurred during the administration of adjuvant trastuzumab. The severity of the clinical presentation and the limited number of reports in the literature of acute trastuzumab-related lung injury make the description of this case of crucial interest.
Get full access to this article
View all access options for this article.
References
1.
Romond
E.
,
Perez
E.A.
,
Bryant
J.
,
Suman
V.
,
Geyer
C.E.
,
Davidson
N.E.
,
Tan-Chiu
E.
,
Martino
S.
,
Paik
S.
,
Kaufman
P.A.
,
Swain
S.M.
,
Pisansky
T.M.
,
Fehrenbacher
L.
,
Kutteh
L.A.
,
Vogel
V.G.
,
Visscher
D.W.
,
Yothers
G.
,
Jenkins
R.B.
,
Brown
A.M.
,
Dakhil
S.R.
,
Mamounas
E.P.
,
Lingle
W.L.
,
Klein
P.M.
,
Ingle
J.N.
,
Wolmark
N.
: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer . N Engl J Med , 353 : 1673 –1684 , 2005 .
2.
Joensuu
H.
,
Kellokumpu-Lehtinen
P.
,
Bono
P.
,
Alanko
T.
,
Kataja
V.
,
Asola
R.
,
Utriainen
T.
,
Kokko
R.
,
Hemminki
A.
,
Tarkkanen
M.
,
Turpeenniemi-Hujanen
T.
,
Jyrkkiö
S.
,
Flander
M.
,
Helle
L.
,
Ingalsuo
S.
,
Johansson
K.
,
Jääskeläinen
A.
,
Pajunen
M.
,
Rauhala
M.
,
Kaleva-Kerola
J.
,
Salminen
T.
,
Leinonen
M.
,
Elomaa
I.
,
Isola
J.
: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer . N Engl J Med , 354 : 809 –820 , 2006 .
3.
Piccart-Gebhart
M.J.
,
Procter
M.
,
Leyland-Jones
B.
,
Goldhirsch
A.
,
Untch
M.
,
Smith
I.
,
Gianni
L.
,
Baselga
J.
,
Bell
R.
,
Jackisch
C.
,
Cameron
D.
,
Dowsett
M.
,
Barrios
C.H.
,
Steger
G.
,
Huang
C.
,
Andersson
M.
,
Inbar
M.
,
Lichinitser
M.
,
Láng
I.
,
Nitz
U.
,
Iwata
H.
,
Thomssen
C.
,
Lohrisch
C.
,
Suter
T.M.
,
Rüschoff
J.
,
Süt
T.
,
Greatorex
V.
,
Ward
C.
,
Straehle
C.
,
McFadden
E.
,
Dolci
M.S.
,
Gelber
R.D.
: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer . N Engl J Med , 353 : 1659 –1672 , 2005 .
4.
Goldhirsch
A.
,
Wood
W.C.
,
Gelber
R.D.
,
Coates
A.S.
,
Thurlimann
B.
,
Senn
H-J
: Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 . Ann Oncol , 18 : 1133 –1144 , 2007 .
5.
Camus
P.
,
Fanton
A.
,
Bonniaud
P.
,
Camus
C.
,
Foucher
P.
: Interstitial lung disease induced by drugs and radiation . Respiration , 71 : 301 –326 , 2004 .
6.
Fujimori
K.
,
Yokoyama
A.
,
Kurita
Y.
,
Uno
K.
,
Saijo
N.
: Paclitaxel-induced cell-mediated hypersensitivity pneumonitis. Diagnosis using leukocyte migration test, bronchoalveolar lavage and transbronchial lung biopsy . Oncology , 55 : 340 –344 , 1998 .
7.
Vahid
B.
,
Mehrotra
A.
: Trastuzumab (herceptin)-associated lung injury . Respirology , 11 : 655 –658 , 2006 .
8.
Anthoney
D.A.
,
Bone
I.
,
Evans
T.R.
: Inflammatory demyelinating polyneuropathy: a complication of immunotherapy in malignant melanoma . Ann Oncol , 11 : 1197 –1200 , 2000 .
9.
Cleverley
J.R.
,
Screaton
N.J.
,
Hiorns
M.P.
,
Flint
J.D.
,
Müller
N.L.
: Drug-induced lung disease: high-resolution CT and histological findings . Clin Radiol , 57 : 292 –299 , 2002 .